BASF today announced the opening of its world-scale tert. Butylamine (tBA) production plant at the Nanjing Chemical Industry Park in China. The plant, with an annual capacity of 10,000 tons, is wholly-owned by BASF and is integrated into the production facilities of BASF-YPC in Nanjing.
BASF has divested its shares in the joint venture companies, BASF Markor Chemical Manufacturing (Xinjiang) Co., Ltd. and Markor Meiou Chemical (Xinjiang) Co., Ltd. in Korla, China, to Verde Chemical Singapore Pte. Ltd.
Novo Nordisk continues its sizeable manufacturing investments to meet increasing drug demands.
MSD, known as Merck & Co. in the US and Canada, recently announced it will acquire Verona Pharma, a biopharmaceutical company focused on respiratory diseases, for approximately $10 billion.
German oxo-chemicals manufacturer Oxea has appointed Michael McHenry as its new CEO with effect from August 15, 2025.
Swiss pharma heavyweight Roche announced has entered into an exclusive collaboration and licensing agreement with Denmark’s Zealand Pharma. Under the terms of this agreement, the two companies will collaborate to co-develop and co-commercialize petrelintide, Zealand Pharma’s amylin analog as a standalone therapy as well as a fixed-dose combination with Roche’s lead incretin asset CT-388.
